200 related articles for article (PubMed ID: 25370765)
41. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Collette L; de Reijke TM; Schröder FH;
Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
[TBL] [Abstract][Full Text] [Related]
42. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
43. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
44. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
[TBL] [Abstract][Full Text] [Related]
46. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
47. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis.
Zhang LM; Jiang HW; Tong SJ; Zhu HQ; Liu J; Ding Q
Urol Int; 2013; 91(1):38-48. PubMed ID: 23774685
[TBL] [Abstract][Full Text] [Related]
50. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.
Nakata D; Nakao S; Nakayama K; Araki S; Nakayama Y; Aparicio S; Hara T; Nakanishi A
Biochem Biophys Res Commun; 2017 Jan; 483(1):271-276. PubMed ID: 28025139
[TBL] [Abstract][Full Text] [Related]
51. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
52. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Fowler JE; Pandey P; Seaver LE; Feliz TP; Braswell NT
J Urol; 1995 Jun; 153(6):1860-5. PubMed ID: 7538599
[TBL] [Abstract][Full Text] [Related]
53. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
Sartor O; Dong Y
Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
[TBL] [Abstract][Full Text] [Related]
54. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
55. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
Figg WD; Franks ME; Venzon D; Duray P; Cox MC; Linehan WM; Van Bingham W; Eastham JA; Reed E; Sartor O
World J Urol; 2004 Dec; 22(6):425-30. PubMed ID: 15592675
[TBL] [Abstract][Full Text] [Related]
56. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
57. Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.
Cattrini C; Rubagotti A; Zinoli L; Cerbone L; Zanardi E; Capaia M; Barboro P; Boccardo F
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540293
[TBL] [Abstract][Full Text] [Related]
58. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
[TBL] [Abstract][Full Text] [Related]
59. [Predictive factors for bone metastases of prostate cancer].
Chen YH; Nie P; Jiang W; Zhao SJ; Zhang Z; Lin HX; Li MY; Liu YQ; Li PH; Zhu XS
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 36(2):205-9. PubMed ID: 26922017
[TBL] [Abstract][Full Text] [Related]
60. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
